
Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.
The Senior Manager, SEC Reporting will play a critical role in supporting public company readiness initiatives and leading external financial reporting activities. Reporting to the Head of Finance, this individual will be responsible for preparing SEC filings, supporting technical accounting matters, and helping establish scalable reporting and compliance processes appropriate for a public company environment. The ideal candidate will bring strong technical accounting expertise, excellent project management capabilities, and the ability to work independently in a fast-paced clinical-stage biotech environment.
This is an exciting opportunity to join a growing clinical-stage biotechnology company at a transformational stage and help build the infrastructure of a future public company. The role offers meaningful exposure to executive leadership, opportunities for professional growth, and the ability to make a significant impact on the organization’s future success.
Key Responsibilities:
Personal Attributes:
Qualifications:
Required
Preferred
Salary Range
$157,000.00 - $192,000.00 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

Remix is working to transform patient's lives through modulation of RNA processing and addressing drug targets in diseases of high unmet medical need. We are a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).